Skip to main content
Back
GNMLF logo

Genomma Lab Internacional, S.A.B. de C.V.

Data quality: 100%
Oversold
GNMLF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$1.00
$0.00 (0.00%)
Mkt Cap: 973.79M
Day Range
$0.95 $1.00
52-Week Range
$0.93 $1.43
Volume
5,000
50D / 200D Avg
$1.01 / $1.06
Prev Close
$1.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 10.9 0.4
P/B 1.6 2.9
ROE % 1.5 3.7
Net Margin % 9.2 3.8
Rev Growth 5Y % 6.6 10.0
D/E 0.7 0.2

Key Takeaways

Revenue grew 6.58% annually over 5 years — modest growth
Earnings declined -94.03% over the past year
ROE of 1.46% is below average
Generating 46.55M in free cash flow
P/E of 10.92 — trading at a low valuation
Capital efficient — spends only 3.12% of revenue on capex

Growth

Revenue Growth (5Y)
6.58%
Revenue (1Y)9.03%
Earnings (1Y)-94.03%
FCF Growth (3Y)-20.92%

Quality

Return on Equity
1.46%
ROIC14.91%
Net Margin9.16%
Op. Margin21.26%

Safety

Debt / Equity
0.69
Current Ratio1.77
Interest Coverage3.56

Valuation

P/E Ratio
10.92
P/B Ratio1.58
EV/EBITDA5.99
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9.03% Revenue Growth (3Y) 0.18%
Earnings Growth (1Y) -94.03% Earnings Growth (3Y) 18.13%
Revenue Growth (5Y) 6.58% Earnings Growth (5Y) 8.78%
Profitability
Revenue (TTM) 973.01M Net Income (TTM) 89.16M
ROE 1.46% ROA 6.74%
Gross Margin 62.84% Operating Margin 21.26%
Net Margin 9.16% Free Cash Flow (TTM) 46.55M
ROIC 14.91% FCF Growth (3Y) -20.92%
Safety
Debt / Equity 0.69 Current Ratio 1.77
Interest Coverage 3.56 Dividend Yield 0.04%
Valuation
P/E Ratio 10.92 P/B Ratio 1.58
P/S Ratio 1.00 PEG Ratio -0.12
EV/EBITDA 5.99 Dividend Yield 0.04%
Market Cap 973.79M Enterprise Value 1.24B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 973.01M 892.41M 969.48M 862.36M 754.10M
Net Income 89.16M 1.49B 63.89M 71.22M 63.68M
EPS (Diluted) 0.09 1.53 0.07 0.07 0.06
Gross Profit 611.40M 572.23M 593.52M 521.09M 465.65M
Operating Income 206.90M 188.13M 188.96M 169.35M 145.92M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.32B 1.10B 1.22B 1.11B 1.05B
Total Liabilities 705.75M 581.91M 664.14M 587.25M 558.53M
Shareholders' Equity 616.35M 11.59B 552.42M 520.52M 490.44M
Total Debt 424.54M 311.15M 6.24B 330.24M 290.25M
Cash & Equivalents 158.62M 2.38B 1.47B 77.10M 61.59M
Current Assets 712.15M 12.07B 10.67B 579.98M 560.98M
Current Liabilities 401.22M 6.54B 6.62B 479.70M 319.96M